Cspc Zhongnuo Pharmaceutical (shijiazhuang) Co., Ltd.

This Phase 2 trial tests an experimental injection called SYH2068 in 120 adults with high lipoprotein(a), a genetic risk factor for heart disease. Participants receive either the drug or a placebo to see if it safely lowers their Lp(a) levels over several months. The goal is to f…

This Phase 3 trial tests aprocitentan, a drug already approved in some countries, for people with resistant hypertension—high blood pressure that stays high despite taking three or more medications. About 382 adults will receive either the drug or a placebo for 8 weeks. The main …

This Phase 2 trial tests an injection called SYH2070 in 18 Chinese adults with homozygous familial hypercholesterolemia (HoFH), a rare genetic condition causing extremely high cholesterol. Participants receive the drug for 48 weeks to see if it safely lowers their LDL cholesterol…

This study compares a new injectable form of aripiprazole (SYH9096) to the approved drug Abilify Maintena® in 116 adults with stable schizophrenia. Participants receive five injections of each version, one month apart, to see if the new version reaches similar drug levels in the …

This Phase 3 trial tests an injection called SYH2053 for people with heterozygous familial hypercholesterolemia (HeFH), a genetic condition causing very high LDL cholesterol. About 135 adults on stable statin therapy will receive either the drug or a placebo. The main goal is to …

This Phase 3 trial tests an injection called SYH2053 for people with high cholesterol that isn't controlled by standard pills. About 900 adults aged 18-75 will receive either the drug or a placebo, on top of their usual cholesterol medication. The main goal is to see if SYH2053 s…